KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $660.9 million.

  • AbCellera Biologics' Non-Current Assets rose 167.81% to $660.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $660.9 million, marking a year-over-year increase of 167.81%. This contributed to the annual value of $609.2 million for FY2024, which is 112.42% down from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Non-Current Assets is $660.9 million, which was up 167.81% from $659.9 million recorded in Q2 2025.
  • AbCellera Biologics' Non-Current Assets' 5-year high stood at $660.9 million during Q3 2025, with a 5-year trough of $220.5 million in Q1 2021.
  • In the last 5 years, AbCellera Biologics' Non-Current Assets had a median value of $579.2 million in 2025 and averaged $525.1 million.
  • In the last 5 years, AbCellera Biologics' Non-Current Assets skyrocketed by 10226.16% in 2021 and then crashed by 1077.07% in 2025.
  • Quarter analysis of 5 years shows AbCellera Biologics' Non-Current Assets stood at $388.8 million in 2021, then surged by 32.58% to $515.4 million in 2022, then rose by 19.54% to $616.1 million in 2023, then fell by 1.12% to $609.2 million in 2024, then rose by 8.48% to $660.9 million in 2025.
  • Its Non-Current Assets stands at $660.9 million for Q3 2025, versus $659.9 million for Q2 2025 and $579.2 million for Q1 2025.